Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Nuvolone

Showing results (11-20 of 115) with videos related to

Pageof 12
Sort By:
Frontiers in Pharmacology|August 6, 2020
Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic AmyloidosesAlice Nevone, Giampaolo Merlini, Mario Nuvolone
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 12, 2022
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic AmyloidosisMario Nuvolone, Alice Nevone, Giampaolo Merlini
Nature Reviews. Immunology|November 6, 2013
The immunobiology of prion diseasesAdriano Aguzzi, Mario Nuvolone, Caihong Zhu
International Journal of Molecular Sciences|December 23, 2022
Oral Therapy for the Treatment of Transthyretin-Related Amyloid CardiomyopathyMario Nuvolone, Maria Girelli, Giampaolo Merlini
Expert Opinion on Drug Safety|February 15, 2021
A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosisMario Nuvolone, Marco Basset, Giovanni Palladini
Circulation|January 21, 2025
AL or ATTR Amyloidosis? Never Two Without ThreeMario Nuvolone, Giuseppe D Sanna, Giovanni Palladini
JACC. Heart Failure|August 23, 2024
The Pathophysiological and Therapeutic Implications of Cardiac Light-Chain Amyloidosis Compared With Transthyretin AmyloidosisJoel D Schilling, Mario Nuvolone, Giampaolo Merlini
European Journal of Internal Medicine|May 27, 2018
Management of the elderly patient with AL amyloidosisMario Nuvolone, Paolo Milani, Giovanni Palladini, et al.
Expert Review of Hematology|July 30, 2020
Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedsideMarco Basset, Mario Nuvolone, Giovanni Palladini, et al.
Plos One|February 12, 2015
Prion pathogenesis in the absence of NLRP3/ASC inflammasomesMario Nuvolone, Silvia Sorce, Petra Schwarz, et al.
Pageof 12

Showing results (11-20 of 115) with videos related to

Sort By:
Pageof 12
Frontiers in Pharmacology|August 6, 2020
Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic AmyloidosesAlice Nevone, Giampaolo Merlini, Mario Nuvolone
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 12, 2022
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic AmyloidosisMario Nuvolone, Alice Nevone, Giampaolo Merlini
Nature Reviews. Immunology|November 6, 2013
The immunobiology of prion diseasesAdriano Aguzzi, Mario Nuvolone, Caihong Zhu
International Journal of Molecular Sciences|December 23, 2022
Oral Therapy for the Treatment of Transthyretin-Related Amyloid CardiomyopathyMario Nuvolone, Maria Girelli, Giampaolo Merlini
Expert Opinion on Drug Safety|February 15, 2021
A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosisMario Nuvolone, Marco Basset, Giovanni Palladini
Circulation|January 21, 2025
AL or ATTR Amyloidosis? Never Two Without ThreeMario Nuvolone, Giuseppe D Sanna, Giovanni Palladini
JACC. Heart Failure|August 23, 2024
The Pathophysiological and Therapeutic Implications of Cardiac Light-Chain Amyloidosis Compared With Transthyretin AmyloidosisJoel D Schilling, Mario Nuvolone, Giampaolo Merlini
European Journal of Internal Medicine|May 27, 2018
Management of the elderly patient with AL amyloidosisMario Nuvolone, Paolo Milani, Giovanni Palladini, et al.
Expert Review of Hematology|July 30, 2020
Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedsideMarco Basset, Mario Nuvolone, Giovanni Palladini, et al.
Plos One|February 12, 2015
Prion pathogenesis in the absence of NLRP3/ASC inflammasomesMario Nuvolone, Silvia Sorce, Petra Schwarz, et al.
Pageof 12